Compare SELLAS Life Sciences Group Inc. Common Stock (SLS) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SELLAS Life Sciences Group Inc. Common Stock vs Williams-Sonoma, Inc. — how do they compare? SELLAS Life Sciences Group Inc. Common Stock trades at $11.37 (market cap $2.27B), while Williams-Sonoma, Inc. trades at $239 (market cap $28.15B). The key difference: Williams-Sonoma, Inc. is far larger — about 12.4× SELLAS Life Sciences Group Inc. Common Stock's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| SLS | WSM | |
|---|---|---|
Market Cap | $2.27B | $28.15B |
Volume | 4,179,659 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $15.46 | $251.81 |
52-Week Low | $1.39 | $168.64 |
Enterprise Value | $2.14B | $28.65B |
Typical Hold Time | — | 59 Days |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Williams-Sonoma (WSM) trades at $240.46, down 0.74% on the day, with a bullish technical signal and strong profitability metrics. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights market share gains, margin expansion, and new store openings, reinforcing positive business momentum.
The outlook remains favorable given earnings outperformance and raised guidance, though valuation multiples are elevated. Key risks include housing market sensitivity and competitive pressures. Analyst consensus is mixed but leans positive, with a price target suggesting modest upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SELLAS Life Sciences Group Inc. Common Stock
SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
